Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (276)
Related Products (276)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
(E/Z)-Rilzabrutinib
0 ImagesCat. No.: HY-151232CAS No.: 1575591-66-0Synonyms: (E/Z)-PRN1008(E/Z)-Rilzabrutinib ((E/Z)-PRN1008) is a cis-trans isomer of Rilzabrutinib (HY-112166). Rilzabrutinib is a BTK inhibitor.
-
Terreic acid
0 ImagesTerreic acid, a quinone epoxide antibiotic, acts as an effective Btk inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC50 of approximately 100 μM.
-
PTD10
0 ImagesCat. No.: HY-154860CAS No.: 2642231-19-2PTD10 is a selective and potent BTK PROTAC degrader (DC50 = 0.5 nM, KD = 2.28 nM). PTD10 can recruit cereblon (CRBN) E3 ligase and form a ternary complex with BTK, thereby mediating the ubiquitination and proteasome-dependent degradation of BTK. PTD10 inhibits cancer cells proliferation, and induces cell apoptosis via activation of the caspase-dependent pathway and mitochondrial pathway. PTD10 potently inhibits the BCR, AKT and NF-κB signaling pathway. PTD10 can be used for researches of B-cell malignancies and autoimmune disease.
-
(R)-Pirtobrutinib
0 ImagesSynonyms: (R)-LOXO-305
-
SJF620 hydrochloride
0 ImagesCat. No.: HY-133137ACAS No.: 2821938-05-8
-
GDC-0834 Racemate
0 ImagesCat. No.: HY-15427ACAS No.: 1133432-46-8
-
Dihydrodiol-Ibrutinib-d5
0 ImagesCat. No.: HY-100659SCAS No.: 2068022-09-1Synonyms: PCI-45227-d5Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib.
-
(R)-Elsubrutinib
0 ImagesSynonyms: (R)-ABBV-105(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer.
-
Acalabrutinib (Standard)
0 ImagesSynonyms: ACP-196 (Standard)Acalabrutinib (Standard) is the analytical standard of Acalabrutinib. This product is intended for research and analytical applications. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
DBt-10
0 ImagesCat. No.: HY-156746DBt-10 is a PROTAC degrader that targets and degrades BTK by recruiting DCAF1. It degrades BTK in TMD8 BTK-GFP/mCherry cells with a DC50 of 137 nM. DBt-10 induces CRL4DCAF1-dependent ubiquitination and proteasomal degradation of BTK, and retains BTK-degrading and antiproliferative activities in TMD8 cells that are resistant to CRBN-BTK PROTACs due to loss of CRBN expression. DBt-10 has a high survival window and exhibits extremely weak apoptosis-inducing effects on lymphoma cells. DBt-10 can be used for research on diffuse large B-cell lymphoma.
-
Acalabrutinib maleate
0 ImagesCat. No.: HY-17600ACAS No.: 2242394-65-4Synonyms: Calquence maleate; ACP-196 maleateAcalabrutinib (Calquence) maleate is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib maleate demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib maleate can be used for CLL research. Acalabrutinib maleate is a click chemistry reagent, which contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
BTK inhibitor 13
0 ImagesCat. No.: HY-130255CAS No.: 2376726-26-8BTK inhibitor 13 is an orally active Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 value of 1.2 nM against human BTK. BTK inhibitor 13 covalently modifies the Cys481 residue of BTK when binding to the inactive conformation of BTK. BTK inhibitor 13 is used for the research of autoimmune diseases.
